title: Periorbital Syringomas Treated With an Externally Used 1,444 nm Neodymium-Doped Yttrium Aluminum Garnet Laser.
abstract: BACKGROUND
  The 1,444 nm wavelength is also well absorbed in water making it a possible setting for treatment of cystic lesions such as eccrine hydrocystomas and syringomas.
  
  
  OBJECTIVE
  The authors aimed to investigate the efficacy of an externally used 1,444 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser for the treatment of periorbital syringomas.
  
  
  METHODS
  Nineteen patients with periorbital syringomas were treated twice with the externally used 1,444 nm Nd:YAG laser at 2-month intervals. Laser fluences were delivered to each papule with pulse energy of 160 mJ, 1.6 W of power, and at a 10 Hz pulse rate. Clinical improvement and patient satisfaction were assessed at 2 and 6 months after each treatment. Side effects were also examined.
  
  
  RESULTS
  Clinical improvement of >50% was observed in 68.4% of individuals at 2 months after first treatment (2FT) and in all patients at 6 months after second treatment (6ST). Patient satisfaction of no less than "satisfied" was recorded for 63.2% of patients at 2FT, and in 89.5% of patients at 6ST. Erythema was observed in 63.2% of patients but only at 2FT.
  
  
  CONCLUSIONS
  Externally used 1,444 nm Nd:YAG laser treatment may represent an effective and safe approach for the treatment of periorbital syringomas, resulting in good satisfaction and minimal side effects.
authors.affiliation: *All authors are affiliated with the Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Jun Young
authors.initials: JY
authors.lastname: Kim
authors.forename: Jae Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Kee Yang
authors.initials: KY
authors.lastname: Chung
mesh_terms: D000328:Adult; D000535:Aluminum; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053844:Lasers, Solid-State / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D017060:Patient Satisfaction; D017397:Prefrontal Cortex / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D013544:Sweat Gland Neoplasms / Q000473:pathology / Q000601:surgery*; D018252:Syringoma / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome; D015019:Yttrium
chemical_list: C503779:yttrium-aluminum-garnet; D015019:Yttrium; D000535:Aluminum